Donald W. Glazer Sells 41,463 Shares of Beigene Ltd (BGNE) Stock
Beigene Ltd (NASDAQ:BGNE) Director Donald W. Glazer sold 41,463 shares of the business’s stock in a transaction dated Wednesday, September 28th. The shares were sold at an average price of $30.66, for a total transaction of $1,271,255.58. Following the completion of the transaction, the director now owns 4,881,997 shares in the company, valued at $149,682,028.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Beigene Ltd (NASDAQ:BGNE) opened at 30.81 on Friday. Beigene Ltd has a 52 week low of $22.51 and a 52 week high of $35.60. The firm has a 50 day moving average of $29.97 and a 200-day moving average of $29.07. The company’s market capitalization is $1.01 billion.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.05. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $2.08 million. The company’s quarterly revenue was down 71.4% compared to the same quarter last year. On average, analysts forecast that Beigene Ltd will post ($3.38) earnings per share for the current year.
BGNE has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Beigene from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Cowen and Company restated a “buy” rating on shares of Beigene in a research report on Monday, June 6th. Finally, Maxim Group initiated coverage on shares of Beigene in a research report on Wednesday, September 21st. They issued a “buy” rating and a $41.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $40.00.
Several institutional investors have recently modified their holdings of the company. BlackRock Institutional Trust Company N.A. bought a new position in shares of Beigene during the first quarter worth $112,000. BlackRock Inc. increased its position in shares of Beigene by 3,410.1% in the second quarter. BlackRock Inc. now owns 3,826 shares of the company’s stock worth $114,000 after buying an additional 3,717 shares during the period. Bank of Montreal Can bought a new position in shares of Beigene during the second quarter worth $191,000. Landscape Capital Management L.L.C. bought a new position in shares of Beigene during the first quarter worth $202,000. Finally, Vident Investment Advisory LLC bought a new position in shares of Beigene during the second quarter worth $678,000.
Beigene Company Profile
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Stock Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related stocks with our FREE daily email newsletter.